Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rifaximin modulation of gut microecology in IBS-D
ChiCTR2400082111Phase 4Not yet recruiting
- Sponsor
- Union Hospital
- Start
- Mar 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of rifaximin in Diarrhea-predominant irritable bowel syndrome (IBS-D) (2 arms), sponsored by Union Hospital. Primary endpoints: Fecal metagenome at week 12 and Fecal metabolome at week 12. Planned start Mar 2024; status: not yet recruiting.
02
Drugs
rifaximin
03
Conditions
Diarrhea-predominant irritable bowel syndrome (IBS-D)
Beyond the preview
Go deeper on ChiCTR2400082111.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400082111.